Advertisement

Topics

European Commission approves Roche’s new Esbriet tablet formulation for IPF

19:00 EDT 28 Jun 2017 | Pharmaceutical Technology

The European Commission (EC) has approved a new tablet formulation of Swiss pharmaceutical company Roche’s Esbriet (pirfenidone) to treat patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

Original Article: European Commission approves Roche’s new Esbriet tablet formulation for IPF

NEXT ARTICLE

More From BioPortfolio on "European Commission approves Roche’s new Esbriet tablet formulation for IPF"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...